Barclays Plc Turns Defensive: EM Beta, Gold and Healthcare Over Mega‑Cap Tech

The “biggest buys” widget shows a clear pattern: Barclays is paying up for diversification and durable cashflows while selectively pressing its best secular edges.

On the macro side, EEM is the story. The position explodes to 14.7% of the portfolio, up +44966.7% in shares and about $41.0B in dollar terms. That’s not a tweak; it is a call that emerging markets’ underperformance and cheaper starting valuations now offer better risk‑reward than yet more US large‑cap growth.

SPY and IWM both get mid‑30% share increases, signaling a preference to own the US via indices rather than chase every single‑name winner. GLD is doubled (+108.8% in shares, +$441.7M), classic insurance after a drawdown and a nod to policy and geopolitical risk.

Within equities, Barclays is doubling down on the AI stack, but with discipline:

• Nvidia is raised +18.6% in shares, adding about $2.27B, even with a +193.0% gain vs average cost – they’re saying the AI cycle is earlier than the price suggests.
• TSMC and Qualcomm see +21.5% and +31.0% share bumps, respectively, a clear bet on the global semi supply chain, not just the US headline names.

Banks are being rebuilt as cyclical ballast: JPMorgan (+27.3% shares, +$782.9M), Bank of America (+35.3%) and Morgan Stanley (+44.9%) all grow, indicating comfort with credit quality and the rate backdrop. On the defensive growth side, Walmart’s shares jump +135.0% (+$1.19B) and Coca‑Cola +58.1%, while healthcare becomes a second anchor: new AstraZeneca at $1.08B, plus big adds in Johnson & Johnson (+52.3% shares), Merck (+58.3%) and incremental Eli Lilly. This is Barclays consciously building a pharma complex as a core, not a sideshow.

If the buys are about broadening the base, the sells are textbook profit‑taking in crowded leaders and a quiet admission that some narratives ran too hot.

The sharpest cuts are in high‑beta consumer and story stocks:

• Tesla is down -22.6% in shares (about -$1.14B) despite a +78.1% gain vs average cost, signaling they’d rather recycle that upside than stay overexposed to EV cyclicality.
• Amazon (-11.0%, -$797.8M) and Netflix (-27.1%, -$601.7M) are trimmed after strong gains; the message is that consumer internet beta is now better owned via SPY/IWM than via idiosyncratic risk.
• Costco (-25.1%, -$357.0M) and Home Depot (-26.1%) are reduced, hinting at caution on US discretionary spend and housing‑linked demand.

In tech, this is not a growth capitulation but a risk rebalance.

• Alphabet’s GOOGL line is cut -8.0% (-$509.2M) even though it’s up +207.8% vs cost, and Palantir is taken down -30.9% (-$552.4M), classic “sell what worked and was speculative.”
• Broadcom, Micron, AMD, Applied Materials, Lam Research, Analog Devices and KLA all see double‑digit share trims, even from very profitable levels. Barclays is effectively saying the AI and semi cycle is real, but the price risk in the second‑tier and capital‑equipment names is no longer attractive vs owning Nvidia, TSMC and Qualcomm.

They also bleed some financial and quality cyclicals – Berkshire Hathaway (-11.0%, -$365.2M), Goldman Sachs (-11.0%), Honeywell (-14.4%), Linde (-8.8%) – using them as funding sources for the new defensive and macro sleeves.

The sector bar chart shows what the trade blotter already implies: Barclays is deliberately flattening its tech spike and building a three‑pillar book of macro beta, healthcare defensives and still‑meaningful growth.

Technology’s share of the top‑50 drops from an estimated 57.39% to 41.76%. But inside that, they’re pivoting from “everything AI‑adjacent” to a tighter core of Nvidia, Microsoft, Apple and key enablers like TSMC, Intel and Qualcomm. The long tail of semi equipment and speculative software is being shaved.

The biggest gainer is the “unclassified” bucket, which in practice means ETFs and gold: from 6.8% to 31.13%. That jump is EEM, SPY, IWM and GLD – a wholesale move toward instruments that smooth idiosyncratic risk and let Barclays express macro and regional views more cleanly.

Cyclicals are being nudged down. Consumer Discretionary falls from 11.07% to 7.43%, Industrials from 6.9% to 4.45%, Energy from 1.77% to 1.3%, and Real Estate‑labeled payments (Visa, Mastercard) from 3.62% to 2.39%. Finance is roughly steady at 4.34% vs 4.94%, but with more weight in classic banks and brokers than in Berkshire.

Health care edges up from 3.45% to 3.89% as AstraZeneca joins J&J, Eli Lilly, AbbVie and Merck. Consumer Staples and Utilities are small but incrementally larger, thanks mainly to Coca‑Cola and a steady American Electric Power. The net effect: a portfolio still levered to growth, but with a newly built shock absorber made of ETFs, gold and big‑pharma cashflows.

Put together, Barclays is acting like a manager who still believes in the AI and structural‑growth story, but no longer trusts narrow US mega‑cap leadership to carry the entire risk budget.

The colossal EEM allocation says they expect a handoff: weaker dollar or easing financial conditions funneling flows toward emerging markets, where valuations are less stretched. At the same time, doubling GLD and topping up banks indicates they’re hedging both inflation and policy error while keeping a seat at the financials table.

Within equities, owning more Nvidia, TSMC, Qualcomm and the big platforms (Microsoft, Apple) but less of the second‑tier semis and hyper‑growth software is a bet that AI economics will accrue to a relatively small group of winners. Cutting Tesla, Amazon, Netflix and Costco back to size and buying Walmart, Coca‑Cola and a pharma basket is a quiet rotation toward resilience if growth cools.

Going forward, expect Barclays to keep expressing its macro views via ETFs and gold rather than levering single names further. If the next leg of the cycle favors non‑US assets, defensives and high‑quality growth over speculative stories, this 2026‑Q1 book looks like it has already moved to where the puck is going, not where it has been.